ProfileGDS5678 / 1439424_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 65% 64% 63% 64% 63% 63% 63% 62% 69% 64% 64% 63% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8367664
GSM967853U87-EV human glioblastoma xenograft - Control 23.9313365
GSM967854U87-EV human glioblastoma xenograft - Control 33.8261864
GSM967855U87-EV human glioblastoma xenograft - Control 43.7629863
GSM967856U87-EV human glioblastoma xenograft - Control 53.7685764
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8636663
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8606463
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7981163
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7179562
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2304969
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8055164
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8016164
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8101363
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8135964